- Coordinator
- Elicera Therapeutics AB, Sweden
- Runs
- 1 October 2022 to 30 September 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190129097
What the project is doing
In the project's own words, from its summary on CORDIS.
Elicera developed a universally compatible technology platform called iTANK (ImmunoTherapies Activated with NAP for efficient Killing) to enhance the efficacy of current and under development CAR-T cell therapies by inducing a dual mechanism-of-action in the treatment of lymphomas and solid tumours. Elicera’s iTANK platform can circumvent major challenges of CAR-T cells in the treatment of solid tumours, such as antigen heterogenicity, local immunosuppression, and CAR T-cell exhaustion.
As such, the iTANK platform has a potential to revolutionise the landscape of the immuno-oncologyOur innovation arms CAR-T cells with NAP from H.pylori which induces a pro-inflammatory microenvironment and activates the patient’s own CD8+ killer T-cells against the whole repertoire of relevant tumour antigen targets. When tumour cells are killed, NAP-activated dendritic cells can take up tumour-associated antigens and prime killer T-cells against these antigens overcoming problems for CAR-T therapy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Elicera Therapeutics AB | Goteborg | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI